Patents by Inventor Zhengtao LI

Zhengtao LI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101590
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Application
    Filed: February 22, 2023
    Publication date: March 28, 2024
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
  • Publication number: 20230356532
    Abstract: An ink cartridge and a printing apparatus using the same. The ink cartridge includes an ink cartridge body, a chip and a chip holder, and the chip is fixed on the chip holder; when the ink cartridge is installed on the printer along an installation direction, the printer may drive the chip holder to linearly move along a top surface of the ink cartridge body, the chip holder is located at a first position before linearly moving and located at a second position after linearly moving; the chip at the first position is closer to the top surface of the ink cartridge body than at the second position, and when the chip holder is at the second position, the chip abuts against the stylus. The ink cartridge and printing apparatus achieve a higher stability of the electrical connection of the chip and the stylus in a printer.
    Type: Application
    Filed: July 18, 2023
    Publication date: November 9, 2023
    Applicant: ZHUHAI NINESTAR MANAGEMENT CO., LTD.
    Inventors: Jingzhang XIA, Shichao LIANG, Zhengtao LI
  • Publication number: 20230250095
    Abstract: The present disclosure relates to benzimidazole derivatives, a preparation method therefor and a medical use thereof. Specifically, the present disclosure relates to a benzimidazole derivative represented by the general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and its use as a therapeutic agent, in particular its use for the treatment of diseases related to P2X3 activity.
    Type: Application
    Filed: August 13, 2021
    Publication date: August 10, 2023
    Inventors: Wenming LI, Ning LIU, Biao LIU, Haomiao LIU, Jian YU, Hao ZOU, Wei ZHU, Zhengtao LI, Zhen ZHANG, Yunfei LI
  • Patent number: 11634451
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 25, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
  • Publication number: 20220380385
    Abstract: Disclosed are a pyrimidine five-membered nitrogen heterocyclic derivative, a preparation method thereof and the pharmaceutical use thereof. Specifically disclosed are a pyrimidine five-membered nitrogen heterocyclic derivative represented by general formula (II), a preparation method thereof, a composition containing the derivative, and the use thereof as an SHP2 inhibitor and in the preparation of a medicament for preventing and/or treating tumors or cancer.
    Type: Application
    Filed: June 28, 2020
    Publication date: December 1, 2022
    Inventors: Hao ZOU, Zhengtao LI, Yuanhao WANG, Jian YU, Wei ZHU
  • Patent number: 11504375
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: November 22, 2022
    Assignee: DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
    Inventors: Zhengtao Li, Hao Zou, Wei Zhu, Changmao Shen, Rumin Wang, Wengeng Liu, Xiang Chen, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Patent number: 11447492
    Abstract: Disclosed are quinazoline compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds which are useful in treating diseases associated ErbBs. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: September 20, 2022
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Zhengtao Li, Wei Zhong, Jiabing Wang, Qingbei Zeng, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20220073521
    Abstract: The present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative, a preparation method therefor, and the medical uses thereof. Particularly, the present invention relates to a pyrimidine and a five-membered nitrogen heterocycle derivative represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, and the uses thereof as a SHP2 inhibitor for use in the prevention and/or treatment of tumor or cancer, wherein each substituent in the general formula (I) is as defined in the description.
    Type: Application
    Filed: November 29, 2019
    Publication date: March 10, 2022
    Inventors: Hao Zou, Zhengtao Li, Yuanhao Wang, Jian Yu, Wei Zhu
  • Patent number: 11194997
    Abstract: A method and a system for thermal infrared facial recognition are provided. The method includes: determining a thermal infrared facial image to be recognized; inputting the thermal infrared facial image to be recognized into a trained three-sense component extractor to position eyes, a nose, and a mouth of a face in the image, and to perform regional positioning of a left eye, a right eye, the nose, and the mouth, so as to constitute a corresponding key region group; performing affine transformation on the thermal infrared facial image to be recognized using a difference between a key region group of a standard face and the key region group of the face to be recognized; inputting a thermal infrared image after face alignment calibration into a trained facial feature extraction to extract corresponding facial features; and inputting the extracted facial features into a trained classifier to recognize information of an owner.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: December 7, 2021
    Assignee: NANJING HUATU INFORMATION TECHNOLOGY CO., LTD.
    Inventors: Tianxu Zhang, Xuan Su, Zhengtao Li, Shijia Guo, Ting Guo, Ya Peng
  • Publication number: 20210252005
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Application
    Filed: April 7, 2021
    Publication date: August 19, 2021
    Inventors: Zhengtao LI, Hao ZOU, Wei ZHU, Changmao SHEN, Rumin WANG, Wengeng LIU, Xiang CHEN, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 11007198
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 18, 2021
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Zhengtao Li, Hao Zou, Wei Zhu, Changmao Shen, Rumin Wang, Wengeng Liu, Xiang Chen, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20210009587
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Application
    Filed: September 23, 2020
    Publication date: January 14, 2021
    Inventors: Zhengtao LI, Wei ZHONG, Jiabing WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 10822334
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: November 3, 2020
    Inventors: Zhengtao Li, Wei Zhong, Jiabing Wang, Qingbei Zeng, Honchung Tsui, Zhenfan Yang, Xiaolin Zhang
  • Publication number: 20200317669
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Zhengtao LI, Wei ZHONG, Jiabing WANG, Qingbei ZENG, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Publication number: 20200316079
    Abstract: Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Zhengtao LI, Hao ZOU, Wei ZHU, Changmao SHEN, Rumin WANG, Wengeng LIU, Xiang CHEN, Honchung TSUI, Zhenfan YANG, Xiaolin ZHANG
  • Patent number: 10626138
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: April 21, 2020
    Assignees: THE SCRIPPS RESEARCH INSTITUTE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
    Inventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
  • Publication number: 20200040027
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Application
    Filed: July 22, 2019
    Publication date: February 6, 2020
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
  • Publication number: 20200017540
    Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.
    Type: Application
    Filed: August 8, 2019
    Publication date: January 16, 2020
    Inventors: Floyd E. ROMESBERG, Denis A. MALYSHEV, Lingjun LI, Thomas LAVERGNE, Zhengtao LI
  • Patent number: 9557177
    Abstract: The present invention discloses a multi-sensor merging based super-close distance autonomous navigation apparatus and method. The apparatus includes a sensor subsystem, an information merging subsystem, a sensor scanning structure, and an orientation guiding structure, wherein a visible light imaging sensor and an infrared imaging sensor are combined together, and data are acquired by combining a passive measurement mode composed of an optical imaging sensor and an active measurement mode composed of a laser distance measuring sensor.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 31, 2017
    Assignee: Huazhong University of Science and Technology
    Inventors: Tianxu Zhang, Sufei Fan, Yimeng Chen, Heng Yao, Zhengtao Li, Zheng Wang, Wei Huang, Zhenghua Huang
  • Publication number: 20160363451
    Abstract: The present invention discloses a multi-sensor merging based super-close distance autonomous navigation apparatus and method. The apparatus includes a sensor subsystem, an information merging subsystem, a sensor scanning structure, and an orientation guiding structure, wherein a visible light imaging sensor and an infrared imaging sensor are combined together, and data are acquired by combining a passive measurement mode composed of an optical imaging sensor and an active measurement mode composed of a laser distance measuring sensor.
    Type: Application
    Filed: February 10, 2015
    Publication date: December 15, 2016
    Inventors: Tianxu ZHANG, Sufei FAN, Yimeng CHEN, Heng YAO, Zhengtao LI, Zheng WANG, Wei HUANG, Zhenghua HUANG